# US 6,730,821 B2 · Transgenic mice containing retina-specific nuclear receptor gene disruptions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,821 B2
- Document ID: US6730821B2
- Status: Granted
- Kind: B2
- Application number: 09/811,361
- Filed: 2001-03-16
- Published: 2004-02-26
- Granted: 2004-05-04
- Earliest claimed: 2000-03-16
- Assignees: Deltagen, Inc.
- Inventors: Catherine Guenther
- Web page: https://patentgrep.com/patent/US6730821B2

## CPC

- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- A01K 67/0276: Knock-out vertebrates
- C12N 15/85: for animal cells
- A01K 2217/072: maintaining or altering function, i.e. knock in
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2217/20: Animal model comprising regulated expression system
- A01K 2227/105: Murine
- A01K 2267/03: Animal model, e.g. for test or diseases
- A01K 2267/0393: Animal model comprising a reporter system for screening tests
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in genes, which are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.

## Claims

### Claim 1

A transgenic mouse comprising a heterozygous disruption in a retina-specific nuclear receptor gene, wherein said disruption in a homozygous state inhibits production of a functional retina-specific nuclear receptor protein resulting in a transgenic mouse exhibiting an eye abnormality.

### Claim 2

A transgenic mouse whose genome comprises a homozygous disruption in an endogenous retina-specific nuclear receptor gene, wherein the transgenic mouse lacks production of functional retina-specific nuclear receptor and exhibits an eye abnormality.

### Claim 3 (depends on 2)

The transgenic mouse of claim 2, wherein the eye abnormality is retinal dysplasia.

### Claim 4 (depends on 2)

A cell or tissue isolated from the transgenic mouse of claim 2.

### Claim 5

A method of producing a transgenic mouse comprising a disruption in an endogenous retina-specific nuclear receptor gene, the method comprising:
(a) introducing a targeting vector which disrupts the endogenous retina-specific nuclear receptor gene in a mouse embryonic stem cell;
(b) selecting the embryonic stem cell whose genome comprises disrupted retina-specific nuclear receptor gene;
(c) introducing the embryonic stem cell of step (b) into a blastocyst;
(d) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse;
(d) breeding the chimeric mouse to produce the transgenic mouse comprising a heterozygous disruption in the retina-specific nuclear receptor gene; and
(e) breeding the transgenic mouse of step (d) to produce a trans genic mouse whose genome comprises a homozygous disruption of the retina-specific nuclear receptor gene such that the mouse lacks production of functional retina-specific nuclear receptor and exhibits an eye abnormality.

### Claim 6 (depends on 5)

The method of claim 5, wherein the eye abnormality is retinal dysplasia.
